ATE530198T1 - Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist - Google Patents
Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt istInfo
- Publication number
- ATE530198T1 ATE530198T1 AT06723047T AT06723047T ATE530198T1 AT E530198 T1 ATE530198 T1 AT E530198T1 AT 06723047 T AT06723047 T AT 06723047T AT 06723047 T AT06723047 T AT 06723047T AT E530198 T1 ATE530198 T1 AT E530198T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- mmp
- replaced
- furine
- immunotoxin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 7
- 108091005804 Peptidases Proteins 0.000 title abstract 3
- 239000004365 Protease Substances 0.000 title abstract 3
- 239000002596 immunotoxin Substances 0.000 title abstract 3
- 231100000608 immunotoxin Toxicity 0.000 title abstract 3
- 229940051026 immunotoxin Drugs 0.000 title abstract 3
- 230000002637 immunotoxin Effects 0.000 title abstract 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 title 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 title 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 title 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 title 1
- 102000004961 Furin Human genes 0.000 abstract 2
- 108090001126 Furin Proteins 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65311205P | 2005-02-16 | 2005-02-16 | |
| PCT/EP2006/001421 WO2006087196A2 (en) | 2005-02-16 | 2006-02-16 | Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530198T1 true ATE530198T1 (de) | 2011-11-15 |
Family
ID=36916817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06723047T ATE530198T1 (de) | 2005-02-16 | 2006-02-16 | Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090214543A1 (de) |
| EP (1) | EP1848462B1 (de) |
| JP (1) | JP5014157B2 (de) |
| AT (1) | ATE530198T1 (de) |
| CA (1) | CA2597638A1 (de) |
| WO (1) | WO2006087196A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668017A1 (en) * | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Improved conjugates |
| CA2698357C (en) * | 2007-09-04 | 2017-06-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EP3253419A1 (de) | 2015-02-02 | 2017-12-13 | The University of Birmingham | Zieleinheit-peptidepitopkomplexe mit einer vielzahl von t-zell-epitopen |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| AU716564B2 (en) * | 1996-11-06 | 2000-03-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Protease-activatable pseudomonas exotoxin A-like proproteins |
| CA2826735C (en) * | 2003-04-30 | 2019-06-04 | University Of Zurich | Methods for treating cancer using an immunotoxin |
-
2006
- 2006-02-16 AT AT06723047T patent/ATE530198T1/de not_active IP Right Cessation
- 2006-02-16 JP JP2007555528A patent/JP5014157B2/ja not_active Expired - Fee Related
- 2006-02-16 EP EP06723047A patent/EP1848462B1/de not_active Not-in-force
- 2006-02-16 CA CA002597638A patent/CA2597638A1/en not_active Abandoned
- 2006-02-16 WO PCT/EP2006/001421 patent/WO2006087196A2/en not_active Ceased
- 2006-02-16 US US11/816,477 patent/US20090214543A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090214543A1 (en) | 2009-08-27 |
| JP5014157B2 (ja) | 2012-08-29 |
| EP1848462A2 (de) | 2007-10-31 |
| EP1848462B1 (de) | 2011-10-26 |
| WO2006087196A2 (en) | 2006-08-24 |
| WO2006087196A3 (en) | 2007-04-19 |
| JP2008530164A (ja) | 2008-08-07 |
| CA2597638A1 (en) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA90209C2 (ru) | Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров | |
| IL258880A (en) | Diarylhydantoin compounds | |
| ATE459653T1 (de) | Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen | |
| NO20084480L (no) | Diaryltiohydantoin forbindelser | |
| ATE539060T1 (de) | Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| EP1622608A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| UA91910C2 (ru) | Композиция для борьбы с заболеваниями, вызванными фитопатогенными микроорганизмами, и способ борьбы с заболеваниями, вызванными фитопатогенными микроорганизмами, на полезных растениях или на материале для их размножения | |
| MX2010003325A (es) | Anticuepos novedosos. | |
| DE602006012013D1 (de) | Proteasom-hemmer und verwendungsverfahren dafür | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| MXPA06012500A (es) | Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo. | |
| SA523451582B1 (ar) | Ccr8 الأجسام المضادة لـ | |
| ATE527350T1 (de) | Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen | |
| ATE530198T1 (de) | Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist | |
| ATE486892T1 (de) | Verfahren zur kontrolle von krebs | |
| ATE413441T1 (de) | Verfahren zur befestigung und sicherung von ufern,abhängen, böschungen und zumindest teilweise in bewegten gewässern befindlichen bauwerken durch verbundstoffe aus mineralischen partikeln und einem epoxydharz | |
| NZ741573A (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| MX2008016269A (es) | Fermentacion y purificacion de cromoproteinas actinomadura y especies relacionadas. | |
| ATE361914T1 (de) | Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen | |
| ZA202306754B (en) | Half-life extending moieties and methods of using the same | |
| Andreen | No virtue like necessity: dealing with nonpoint source pollution and environmental flows in the face of climate change | |
| DE602006009786D1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
| DE502005001441D1 (de) | Verwendung von speziellen polyolen zur kristallisationsinhibierung von oniumaldehyden bzw. -ketonen | |
| Kwaning et al. | Review on Effects of Mining in Ghana: The Case of Obuasi Municipality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |